Antag Therapeutics has announced the closing of an €80 million Series A financing round to develop AT-7687, a novel therapy targeting obesity. The round was led by Versant Ventures, with Novo Holdings ...

Immunocore has announced that Kimmtrak (tebentafusp) has been recommended for funding in England by the National Institute ...

Orbit Discovery, based in Oxford, UK, and Evergreen Theragnostics, headquartered in Springfield, NJ, USA, have announced the ...

Argenx’s investigational therapy, subcutaneous efgartigimod alfa, has been granted Promising Innovative Medicine (PIM) status ...

New SureSeq CLL + CNV V3 panel improves understanding of CLL OGT has announced the launch of its enhanced SureSeq CLL + CNV ...

A new treatment for asthma and COPD attacks could revolutionise patient care, scientists say. An injection given during ...